SPHK1 and prostate carcinoma: This is supported by the observation that circulating S1P levels were reduced in prostate cancer patients when compared to control subjects or patients with benign hyperplasia [141], despite the reported up-regulation of SPHK1 in prostate cancer specimens [90].